TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with 5 to 20 clinically typical, visible and discrete AKs within a treatment area of sun-damaged skin on the full balding scalp (the balding part of the scalp should be greater than 25 cm2 (4 in2) and up to approximately 250 cm2 (40 In2)~* Subjects with minimum 3 clinically typical, visible and discrete AKs within a tracking area of 50 cm2 (8 In2). The tracking area must be within the treatment area~Exclusion Criteria:~* Location of the treatment area (full balding scalp) within 5 cm of an incompletely healed wound or within 5 cm of a suspected BCC or SCC~* Treatment with ingenol mebutate gel in the treatment area within the last 12 months~* Lesions in the treatment area that have: atypical clinical appearance (e.g. hyperthrophic, hyperkeratotic or cutaneous horns) and /or, recalcitrant disease (e.g. did not respond to cryotherapy on two previous occasions)~* History or evidence of skin conditions other than the trial indication that would interfere with the evaluation of the trial medication (e.g. eczema, unstable psoriasis, xeroderma pigmentosum)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LEO 43204 (Type: EXPERIMENTAL): Treatment once daily for 3 days
- Vehicle gel (Type: PLACEBO_COMPARATOR): Treatment once daily for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosed with Mantle Cell Lymphoma and has had at least one chemotherapy.~2. Subjects must have measurable or evaluable disease.~3. ECOG Performance Status of 0-2.~4. Must be referred for treatment with ibrutinib.~5. Must have adequate organ function.~Exclusion Criteria:~1. Subject is pregnant.~2. Prior malignancy (except nonmelanomatous skin cancer) unless disease free for a minimum of 2 years; non-invasive conditions such as carcinoma in situ of the breast, oral cavity, or cervix are all permissible.~3. Known CNS lymphoma.~4. Prior or current treatment with certain medications. Talk to Study Contact for specifics.~5. Subject is at high risk for TLS.~6. Subject has malabsorption syndrome or other condition which may affect an enteral route of administration.~7. Subject has known contraindication or allergy to both xanthine oxidase inhibitors and rasburicase.~8. Significant history of heart disease.~9. Subject has an active infection.~10. Known active Hepatitis B or Hepatitis C.~11. A serious uncontrolled medical disorder that in the opinion of the investigator would impair the ability of the subject to receive protocol therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABT-199 and Ibrutinib Combination (Type: EXPERIMENTAL): Participants will take ABT-199 (dose 100-400 mg) and Ibrutinib (dose 280-560 mg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 30 and 80 years~* Patients with type 2 diabetes on treatment (HbA1c 6.0-11.0%)~* Carotid plaque on 3D ultrasound~Exclusion Criteria:~* Acute bleeding or bleeding tendency~* Diagnosed with heart failure~* Suggestive of ischemia on ECG~* Uncontrolled hypertension~* Recently diagnosed with peptic ulcer disease~* Taking other antiplatelet agents~* Hypersensitivity to salicylic acid~* Aspirin induced asthma~* Severe kidney, liver, heart disease

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Cilostazol group (Type: EXPERIMENTAL): Cilostazol 200 mg or maximal tolerate dose
- Aspirin group (Type: ACTIVE_COMPARATOR): Aspirin 100 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Autologous Fibrin Glues for Fistulas Closure

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* older than 18 years~* presence of one or more fistulas~* fistulas of low-output volume (\< 200ml/24h)~Exclusion Criteria:~* failure to meet inclusion criteria~* mental handicap~* extreme thinness~* fistulous tract length \< 2 cm~* fistulous tract diameter \> 1 cm~* entero-atmospheric fistulas~* Crohn's disease-related fistulas~* any conditions that might impede spontaneous closure of the fistula, such as complex tracts, associated abscesses, residual disease, foreign bodies or distal obstruction~* any conditions that might increase the risk of auto-transfusion, including hypertension, or diabetes; and acquired immune deficiency syndrome (AIDS)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- conservative therapy (Type: SHAM_COMPARATOR): Conservative therapy includes orrection of electrolytic disturbances, suppression of gastric/intestinal secretion with octreotide, nutritional support.
- Application of autologous PRFG (Type: ACTIVE_COMPARATOR): The application of the glues through the external opening of the fistula was controlled by the drainage tube, which was based on fistulography to assure total occlusion of the internal hole. To allow the adhesion of the fibrin glues patch, all fistulous tracts were debrided to produce a smooth surface. At the time of procedures, the two components were mixed together to yield a gelatinous substance. After the FG was instilled, any redundant glue was removed from the external openings.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Caregiver Speaks: A Technologically Mediated Storytelling Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. be a designated family caregiver (i.e., a family member or friend providing unpaid care) of a PLWD who is enrolled in hospice care,~2. be at least 18 years old,~3. be involved in decisions related to their loved one's hospice care,~4. have access to a digital camera or other photo-taking device such as a cell phone~5. be willing to photograph images they feel capture their caregiving and bereavement experiences~6. be willing to set up a Facebook account and join the private Facebook group, 7) have access to e-mail for REDCap survey data collection~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Will receive usual hospice care plus measures
- Intervention (Type: EXPERIMENTAL): Will receive photo elicitation intervention and will join a secret Facebook group to share photos with other caregivers

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of non-seminomatous germ cell tumors (NSGCT) as evidenced by 1 of the following criteria:~  * Histologically confirmed NSGCT~ * Clinical evidence of disease AND high serum human chorionic gonadotropin (HCG) or alpha-fetoprotein (AFP) levels~* Clinical stage II-III disease (disseminated disease)~* Testicular, retroperitoneal, or mediastinal primary site~* Poor prognosis disease, meeting 1 of the following criteria:~  * Mediastinal primary site~ * Non-pulmonary visceral metastases~ * One of the following lab values:~    * HCG \> 50,000 UI/L~   * AFP \> 10,000 ng/mL~   * Lactate dehydrogenase \> 10 times upper limit of normal (ULN)~PATIENT CHARACTERISTICS:~Age~* Over 16~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Absolute granulocyte count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* Bilirubin ≤ 1.5 times ULN~Renal~* Creatinine clearance \> 60 mL/min~Other~* No other prior malignancy except basal cell skin cancer~* No HIV positivity~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients receive 4 courses of bleomycin, etoposide, and cisplatin (BEP).
- Arm II (Type: EXPERIMENTAL): Patients receive 1 course of bleomycin, etoposide, and cisplatin (BEP). Patients then receive dose-dense sequential combination chemotherapy comprising cisplatin, etoposide, bleomycin, paclitaxel, oxaliplatin, and ifosfamide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Video Double-Lumen Tube Prospective Randomized Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients need lung isolation for purposed surgery~2. 18 years or older~3. All patients to give written informed consent to participate~Exclusion Criteria:~1. Patient with known tracheobronchial anatomical anomalies~2. Patient requiring emergency operations~3. Patients with known difficult airways~4. Patients where other lung isolation devices may be warranted (tracheostomy, nasal intubation)~5. Patient requiring sizes not available in DLT or VDLT~6. Patients requiring a right sided VDLT or DLT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non-Video Double Lumen Tube (DLT) Group (Type: EXPERIMENTAL): Participants receive a non-video DLT for lung isolation before surgery. Once non-video DLT is in correct place, its final position before surgery checked with a fiberoptic bronchoscopy (FOB).
- Video Double Lumen Tube (VDLT) Group (Type: EXPERIMENTAL): Participants receive a VDLT for lung isolation before surgery. Once VDLT is in correct place, its final position before surgery checked with the camera inside the tube.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must:~  * Have been diagnosed with type 2 diabetes mellitus (T2DM)~ * Have HbA1c between ≥7.0% and ≤10.5%~ * Be on stable treatment with unchanged dose of metformin or metformin plus an SGLT-2 inhibitor for at least 3 months before screening~ * Be of stable weight (± 5%) for at least 3 months before screening~ * Have a BMI ≥25 kilograms per meter squared (kg/m2) at screening~Exclusion Criteria:~* Participants must not:~  * Have type 1 diabetes mellitus~ * Have had chronic or acute pancreatitis any time prior to study entry~ * Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative diabetic retinopathy requiring acute treatment~ * Have disorders associated with slowed emptying of the stomach, or have had any stomach surgeries for the purpose of weight loss~ * Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or blood alanine transaminase (ALT) enzyme level \>3.0 times the upper limit of normal (ULN) for the reference range, as determined by the central laboratory. Participants with nonalcoholic fatty liver disease (NAFLD) are eligible for participation in this trial only if their ALT level is ≤3.0 the ULN for the reference range~ * Have an estimated glomerular filtration rate \<45 mL/minute/1.73 m2 (or lower than the country specific threshold for using the protocol required dose of metformin per local label)~ * Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months~ * Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2~ * Have been taking any other diabetes medicines other than metformin, or metformin plus an SGLT-2 inhibitor during the last 3 months~ * Have been taking weight loss drugs, including over-the-counter medications during the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5 mg Tirzepatide (Type: EXPERIMENTAL): 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
- 10 mg Tirzepatide (Type: EXPERIMENTAL): 10 mg tirzepatide administered SC once a week.
- 15 mg Tirzepatide (Type: EXPERIMENTAL): 15 mg tirzepatide administered SC once a week.
- Insulin Degludec (Type: ACTIVE_COMPARATOR): Insulin degludec administered SC once a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be 50 years of age or older, of either sex, and of any race/ethnicity.~* Subject must have a clinical history of ragweed-induced allergic rhinoconjunctivitis with or without asthma.~* Subject must have a positive skin prick test response to Ambrosia artemisiifolia at the Screening Visit~* Subject must have a forced expiratory volume in 1 second (FEV1) of at least 70% of predicted value at the Screening Visit and at Randomization.~* A subject's clinical laboratory tests, electrocardiogram (ECG) and vital signs conducted at the Screening Visit must be within normal limits or clinically acceptable to the investigator.~Exclusion Criteria:~* Subject with asthma who requires inhaled corticosteroids for the treatment of their asthma during the study period.~* Subject requiring anti-allergy medications during the time period from randomization to study completion.~* Subject who has received an immunosuppressive treatment within 3 months prior to the Screening Visit (except steroids for allergic and asthma symptoms).~* Subject with a history of anaphylaxis with cardiorespiratory symptoms.~* Subject with a history of chronic urticaria or angioedema.~* Subject with current severe atopic dermatitis.~* Female subject who is breastfeeding, pregnant, or intending to become pregnant.~* Subject with a history of allergy, hypersensitivity or intolerance to the ingredients of the investigational medicinal products (IMPs) (except for Ambrosia artemisiifolia), or self-injectable epinephrine.~* Subject with a history of self-injectable epinephrine use.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet sublingual, once daily
- SCH 39641 6 Amb a 1-U (Type: EXPERIMENTAL): 6 Units Short Ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) in an AIT, sublingual, once daily
- SCH 39641 12 Amb a 1-U (Type: EXPERIMENTAL): 12 Amb a 1-U in an AIT, sublingual, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Clinical diagnosis of Parkinson's disease: Gibb and Gelb criteria~* Apathy defined by a score of - 16 or more on the LARS scale (Sockeel et al., 2006)and criteria of Marin (1991)~* No dementia according to DSM IV with MMSE Score≥ 27 and Mattis score≥ 130~* Under stable dopaminergic treatment for 3 months~Exclusion criteria:~* Depression according to DSM-IV criteria and a score \< 18 on the MADRS~* Subthalamic stimulation of less than one year~* Subthalamic stimulation without stable parameters for 3 months~* Subject older than 80 years~* Severe rest tremor with a subscore \> or= 3 on the UPDRS part~* Parkinson related Psychosis in progress~* Hypersensibility to cholinesterase inhibitors or carbamates~* Myocardial infarction, other cardiac affections~* Severe hepatic insufficiency~* Sever medical illness~* Skin diseases interfering with transdermal patch~* Pregnancy~* Incapacity to give the consent

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Active treatment (Type: ACTIVE_COMPARATOR): A: transdermal rivastigmine at 4.6 mg per day during one month then 9.5 mg per day during 5 months.
- placebo (Type: PLACEBO_COMPARATOR): transdermal patch of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy child~* Child vaccinated with 3 doses of HEXAVAC or 3 doses of INFANRIX HEXA as infant~* Child vaccinated with the third dose of HEXAVAC or INFANRIX HEXA at least 10 years prior to challenge dose~Exclusion Criteria:~* Receipt of more than 3 doses of any Hepatitis B containing vaccine~* History of clinical diagnosis of infection due to Hepatitis B~* History or current close contact with known carriers of Hepatitis B virus~* Prior known sensitivity or allergy to any component of HBVAXPRO~* Chronic illness / medical condition that could interfere with study conduct or completion~* Coagulation disorder that would contraindicate intramuscular injection~* Subject is pregnant~* Receipt of corticosteroids for more than 14 days in the 30 days prior to study~* Receipt of Immunoglobulins, blood or blood-derived products in the 3 months prior to study~* Planned participation in another clinical study

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- HBVAXPRO Challenge dose (Type: EXPERIMENTAL): HBVAXPRO 5µg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trastuzumab Based Therapy in HER2 Positive AGC

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. pathology and medical imageology proven advanced gastric adenocarcinoma, inoperable;~2. received trastuzumab plus chemotherapy as the first-line palliative chemotherapy;~3. with measurable lesion with a diameter 20 mm using conventional computed tomography (CT) or magnetic resonance imaging (MRI) scans or 10 mm using spiral CT scans;~4. Eastern Cooperative Oncology Group performance status (ECOG PS ) of 0-2;~5. left ventricular ejection fraction(LVEF) more than 50 percents;~6. sufficient bone marrow, liver and renal function.~Exclusion Criteria:~1. received previous systemic therapy for advanced disease (except adjuvant/neoadjuvant chemotherapy completed at least 6 months before enrollment);~2. trastuzumab based adjuvant/neoadjuvant therapy;~3. treatment with any other anticancer therapy (lapatinib, immunotherapy, etc);~4. patients with heart failure, coronary artery disease or myocardial infarction within the previous 6 months.~5. trastuzumab based first line therapy started beyond 4 weeks from the first diagnoses of AGC.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HER2 positive AGC treated with H+CT (Type: None): HER2 expression was assessed by IHC first. In the cases with IHC 2+, fluorescence in situ hybridization (FISH) was used to detect HER2/neu amplification levels. Only patients with high level of HER2 expression (IHC 3+ or IHC 2+ plus FISH positive) were eligible in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete